Ductal carcinoma

Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy

Retrieved on: 
Sunday, June 4, 2023
TNBC, G1 Therapeutics, TCF7, TIL, Safety, Pembrolizumab, Infiltration, OS, G1, Trae Waynes, Adjuvant therapy, PD-L1, Neoplasm, Carboplatin, PCR, PFS, ASCO, RESEARCH, American Joint Committee on Cancer, Ductal carcinoma, SELL, Hair, TILS, American Society of Clinical Oncology, Memory, Symantec Endpoint Protection, Immune system, Annual general meeting, CD62L, Nausea, PARK, Diagnosis, Poster, Therapy, Tumor microenvironment, Gene, Society, ORR, Neoadjuvant therapy, Fatigue, Taxane, Vaccine, Medical imaging, Trilaciclib, Regulatory T cell, Patient

RESEARCH TRIANGLE PARK, N.C., June 04, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented results from 24 patients enrolled in its Phase 2, single arm mechanism of action study of trilaciclib administered as a single agent to patients with early-stage triple-negative breast cancer (TNBC) prior to receiving trilaciclib and neoadjuvant therapy. These results highlight the potential for trilaciclib to enhance long term immune surveillance by increasing T cell function and generation of certain memory T cells and demonstrate gene expression profiles that may be associated with improved clinical outcome. These data support earlier findings from this Phase 2 trial demonstrating an increase in the ratio of CD8+ T cells to regulatory T cells (Tregs); a high ratio of CD8+ T cell to Tregs is predictive of overall survival (OS) and is associated with pathologic complete response (pCR). As expected, high rates of pCR were observed in patients with PD-L1(+) tumors and in patients with inflamed tumor immune microenvironments.

Key Points: 
  • As expected, high rates of pCR were observed in patients with PD-L1(+) tumors and in patients with inflamed tumor immune microenvironments.
  • Data published by G1 and others show that trilaciclib can promote trafficking of immune cells out of the stroma and into the tumor microenvironment via chemokine release, thus leading to an inflamed tumor immune microenvironment status.
  • Trilaciclib was shown to enhance the number and function of CD8+ T cells in the tumor microenvironment.
  • These results help confirm the role of trilaciclib in increasing the pool of functional memory T cells that could contribute to long-term immune surveillance and efficacy, as measured by longer term endpoints like OS.

NCCN Publishes New Resource to Help Patients Understand Quick-Moving Type of Breast Cancer

Retrieved on: 
Monday, April 24, 2023
Male, IBC, FACP, Metastatic breast cancer, National Comprehensive Cancer Network, Survival, Breast, Language, BSN, Ductal carcinoma, NCCN, Inflammatory breast cancer, MD, Breast cancer, Amazon (company), Patient, Lymph, Division, Translation, Diagnosis, Neoplasm, United, System, Northwestern University, Family, Red, Skin, Medical imaging, Birth control

PLYMOUTH MEETING, Pa., April 24, 2023 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®) has published a new addition to its library of patient resources, expanding the information available for breast cancer. The new NCCN Guidelines for Patients®: Inflammatory Breast Cancer joins patient and caregiver resources for Breast Cancer Screening and Diagnosis, Ductal Carcinoma In Situ, Invasive Breast Cancer, and Metastatic Breast Cancer. Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer—estimated to account for 1-6% of all cases in the United States—that tends to be diagnosed at a younger age.1,2,3

Key Points: 
  • NCCN Guidelines for Patients: Inflammatory Breast Cancer explains how this particular disease type and its treatment approaches are different from more common forms of breast cancer; available at NCCN.org/patientguidelines .
  • The new NCCN Guidelines for Patients®: Inflammatory Breast Cancer joins patient and caregiver resources for Breast Cancer Screening and Diagnosis , Ductal Carcinoma In Situ , Invasive Breast Cancer , and Metastatic Breast Cancer .
  • The NCCN Guidelines for Patients: Inflammatory Breast Cancer are available for free at NCCN.org/patientguidelines or via the NCCN Patient Guides for Cancer App , thanks to funding from the NCCN Foundation®.
  • NCCN's patient resources for breast cancer were recently named the 2022 Excellence in Cancer Patient Education award winner from the Cancer Patient Education Network (CPEN).

PreludeDx™ to Present Comparative Analysis of Treatment Recommendations of Black and White DCIS Breast Cancer Patients Using DCISionRT® at ASBrS 2023 Annual Meeting

Retrieved on: 
Thursday, April 20, 2023
Woman, Ductal carcinoma, Patient, Physician, Medicine, Pregnancy Outcome Prediction study, DCIS, White, Society, Medical imaging

This race/ethnicity data will be presented at the 24th Annual Meeting of the American Society of Breast Surgeons (ASBrS), being held on April 26 – 30, 2023 at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts.

Key Points: 
  • This race/ethnicity data will be presented at the 24th Annual Meeting of the American Society of Breast Surgeons (ASBrS), being held on April 26 – 30, 2023 at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts.
  • Title: A Comparative Analysis of Changes in Treatment Recommendations for Black and White Patients with Ductal Carcinoma in Situ Using a 7-gene Predictive Biosignature: Analysis of the PREDICT Study
    "While there is a significant body of evidence addressing race/ethnic treatment differences among women with invasive breast cancer, there is limited evidence for DCIS.
  • We are excited to present this new and valuable data for DCIS patients," says Dan Forche, President and CEO of PreludeDx.
  • "We are confident that the new DCISionRT data will help guide physicians and their patients to make more informed treatment decisions."

Perimeter Medical Imaging AI Announces Publication of New Clinical Evidence Featuring Case Studies from Commercial Use of Perimeter S-Series OCT

Retrieved on: 
Wednesday, March 29, 2023
Optical coherence tomography, Surgeon, Perimeter, FSE, Ductal carcinoma, International Conference on Software Reuse, Patient, OCT, OTC, Paper, FDA, Conference, Medical imaging, DALLAS

Perimeter S-Series OCT is an ultra-high-resolution medical imaging tool with FDA 510(k) clearance that uses Optical Coherence Tomography (OCT) to provide clinicians with cross-sectional, real-time margin visualization 1-2 mm below the surface of an excised tissue specimen.

Key Points: 
  • Perimeter S-Series OCT is an ultra-high-resolution medical imaging tool with FDA 510(k) clearance that uses Optical Coherence Tomography (OCT) to provide clinicians with cross-sectional, real-time margin visualization 1-2 mm below the surface of an excised tissue specimen.
  • Dr. Amelia Tower, a board-certified general surgeon with advanced training in breast surgical oncology based in Fort Worth, TX, authored the paper and describes how she integrated the Perimeter S-Series OCT system into her breast oncology practice.
  • Jeremy Sobotta, Perimeter's Chief Executive Officer stated, "We are encouraged and excited by the results from the case studies featured in this newly published white paper.
  • We believe that bringing Perimeter's transformative ultra-high resolution medical imaging technology directly into the OR can assist the surgeon with real-time intraoperative margin visualization – with the aim of improving patient outcomes and reducing healthcare costs.

PreludeDx™ Presents New Data at the 40th Annual Miami Breast Cancer Conference Identifying Which Patients with DCIS May Be Undertreated Based on Clinicopathologic Factors Alone

Retrieved on: 
Thursday, March 2, 2023
Patient, CP, Additive effect, Active surveillance of low-risk papillary thyroid microcarcinoma, Washington University School of Medicine, Woman, HT, DCIS, MBCC, FACS, Therapy, Fontainebleau Miami Beach, Conference, Alvin J. Siteman Cancer Center, Breast, Clinical research, MSKCC, Cleveland Clinic, Ductal carcinoma, Memorial Sloan Kettering Cancer Center, RT, Medicine, Poster, IBR, Comparative oncology, Nomogram, BCS, Medical imaging, Nursing, Pharmaceutical industry, Radiation therapy, MD

LAGUNA HILLS, Calif., March 2, 2023 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it will be presenting data comparing risk stratification and radiation benefit (RT) for patients with ductal carcinoma in situ (DCIS) using DCISionRT™ with a clinicopathologic (CP) model similar to the Memorial Sloan Kettering Cancer Center (MSKCC) DCIS nomogram at the 40th Annual Miami Breast Cancer Conference (MBCC), being held on March 2 – 5, 2023 at the Fontainebleau Miami Beach.

Key Points: 
  • The study included 926 DCIS patients from four cohorts who were treated with breast conserving surgery (BCS) or BCS + radiation therapy (RT).
  • The study compared MSKCC DCIS nomogram-like model with the DCISionRT 7-gene biosignature.
  • "DCISionRT provides us the clinical evidence to identify which DCIS patients, despite having low-risk clinicopathologic features, can actually benefit from RT and which patients may safely omit RT."
  • The registry includes females 26 and older who are diagnosed with DCIS and are candidates for BCS and eligible for RT.

Breast Cancer Drugs Global Market Report 2023

Retrieved on: 
Thursday, February 16, 2023
Cataract, Organization, Brain, Spinal cord, Mitosis, Woman, Drug combination, Hospital, Genzyme, Heredity, Ductal carcinoma, HER2, World Health Organization, Breast cancer, Osteoporosis, Novartis, Thrombus, Patient, Geography, EMA, Food, Merative, Pamidronic acid, Cell division, Celgene, European Medicines Agency, Infertility, Triple-negative breast cancer, Eli Lilly, Research report, Enzyme inhibitor, Pregnancy, Partnership, Food and Drug Administration, Prevalence, AstraZeneca, COVID-19, Overalls, Headache, Cancer, Pharmaceutical industry, Birth control, Dietary supplement, European, Anastrozole

Microtubules, that pull the chromosomes apart as a cell divides, are disrupted by these medications.The different types include metastatic breast cancer, triple-negative breast cancer, and others (ductal carcinoma in situ, invasive ductal carcinoma, inflammatory breast cancer, breast cancer during pregnancy, and others).

Key Points: 
  • Microtubules, that pull the chromosomes apart as a cell divides, are disrupted by these medications.The different types include metastatic breast cancer, triple-negative breast cancer, and others (ductal carcinoma in situ, invasive ductal carcinoma, inflammatory breast cancer, breast cancer during pregnancy, and others).
  • As the number of people diagnosed with breast cancer rises, the demand for breast cancer drugs increases, thereby driving the market growth.
  • Adverse side effects caused by the use of breast cancer drugs are acting as a restraint on the breast cancer drugs market.Breast cancer drugs can result in long-term or short-term side effects including headaches, dental issues, osteoporosis, heart problems, cataracts, blood clots, infertility, and others.
  • The breast cancer drugs market research report is one of a series of new reports that provides breast cancer drugs market statistics, including breast cancer drugs industry global market size, regional shares, competitors with a breast cancer drugs market share, detailed breast cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer drugs industry.

PreludeDx™ Enters into Agreement with Medical Cost Containment Professionals, LLC to Process Out-of-Network Claims for its Novel DCIS Test, DCISionRT®

Retrieved on: 
Tuesday, January 24, 2023
IBR, Ductal carcinoma, Patient, DCIS, Physician, MCCP, Medicine, RT, Medical imaging

LAGUNA HILLS, Calif., Jan. 24, 2023 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it has entered into a managed care provider agreement with Medical Cost Containment Professionals LLC (MCCP) to process out-of-network claims for PreludeDx's DCISionRT® test. Under the agreement, MCCP's more than 150,000 providers nationwide and their patients throughout the U.S. will now have access to DCISionRT, the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy (RT) benefit.

Key Points: 
  • LAGUNA HILLS, Calif., Jan. 24, 2023 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it has entered into a managed care provider agreement with Medical Cost Containment Professionals LLC (MCCP) to process out-of-network claims for PreludeDx's DCISionRT® test.
  • Under the agreement, MCCP's more than 150,000 providers nationwide and their patients throughout the U.S. will now have access to DCISionRT, the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy (RT) benefit.
  • "Contracting with wrap networks, such as MCCP, is an excellent means to provide additional physicians and patients with access to our proprietary and unique test, regardless of in/out network status," said Dan Forche, President and CEO of PreludeDx.
  • "MCCP providers and their patients now have personalized information to guide treatment decisions based on the patient's own tumor biology."

PreludeDx™ DCISionRT® Data Presented in Spotlight Presentation at the 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
Friday, December 9, 2022
Therapy, Physician, Recurrence, University of California, San Francisco, MD, National Cancer Institute, Biomarker, Patient, DCIS, Research, Precision medicine, Ductal carcinoma, Biology, Breast cancer, University of Colorado, Risk assessment, Woman, Molecular biology, RT, Radiation therapy, University, Breast, Decision tree, IBR, NG, CP, Risk, Medical imaging

LAGUNA HILLS, Calif., Dec. 9, 2022 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced study results demonstrating that DCISionRT provides patients with ductal carcinoma in situ (DCIS) superior recurrence risk stratification and radiation therapy (RT) benefit prediction compared to commonly used clinicopathologic (CP) features. The data was presented in a spotlight presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • The data was presented in a spotlight presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS).
  • Whereas DCISionRT Low Risk patients, which included about one-third of CP High-Risk patients, had no significant RT benefit, representing a true low risk group.
  • PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide.
  • Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on developing precision breast cancer tools that will impact a patient's treatment decision.

PreludeDx™ Announces Latest Data on DCISionRT® in Multiple Presentations at the 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
Wednesday, November 16, 2022
Technology, University of Tennessee, FACS, Risk assessment, Woman, Patient, HER2, Biology, National Cancer Institute, Decision tree, Precision medicine, Physician, University, DCIS, Breast cancer, University of California, San Francisco, Molecular biology, ASCO, Ductal carcinoma, Company, Research, Poster, Therapy, Associate professor, Breast, CEO, Risk, National, Biomarker, Medical imaging, Radiation therapy, MD, Facebook

"We remain committed to continual improvement of personalized medicine for early-stage breast cancer patients and their clinicians."

Key Points: 
  • "We remain committed to continual improvement of personalized medicine for early-stage breast cancer patients and their clinicians."
  • Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue.
  • PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide.
  • Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on developing precision breast cancer tools that will impact a patient's treatment decision.

GenesisCare and PreludeDx(TM) present compelling Australian-first DCISionRT Study Interim Analysis during Breast Cancer Awareness Month 45% change in treatment recommendations when using DCISionRT

Retrieved on: 
Sunday, October 30, 2022
Royal Melbourne, Hospital, TGA, Breast cancer, Congress, Recurrence, CEO, Doctor of Philosophy, Program, Molecular biology, Radiation, University of California, San Francisco, Woman, Risk, Surgical oncology, Royal Women's Hospital, Cancer, Partnership, Precision medicine, RT, GenesisCare, Biology, Breast, Oncology, DCIS, National, Physician, National Cancer Institute, Research, Technology, University, Interim analysis, Company, BCS, Medical imaging, Pharmaceutical industry, Dentistry, Medicine, Ductal carcinoma, Facebook, Patient

DCIS is a pre-invasive disease of the breast that may lead to invasive breast cancer if untreated.

Key Points: 
  • DCIS is a pre-invasive disease of the breast that may lead to invasive breast cancer if untreated.
  • (2) After breast conserving surgery (BCS) for DCIS, radiation therapy is often used to minimise the risk of recurrence.
  • Radiation therapy recommendation decreased by 70% in patients with a low risk DCISionRT score and increased 29% in patients with elevated risk scores.
  • "GenesisCare, in partnership with PreludeDx, is thrilled to present the interim findings from our Australian-first study," continued Dr Zissiadis.